Last updated: February 20, 2026
What are the primary API suppliers for INREBIC?
INREBIC (fedratinib) is a selective JAK2 inhibitor developed by Sardon Pharmaceuticals, approved by the FDA in 2019 for treating myelofibrosis. The active pharmaceutical ingredient (API) sourcing is crucial for manufacturing scale-up, cost management, and supply chain security.
Major API producers for INREBIC include:
- CMOs (Contract Manufacturing Organizations) in Asia, specifically China and India, known for their capacity in complex small-molecule APIs.
- In-house manufacturing facilities of Sardon Pharmaceuticals, which maintain control over key intermediates and final API synthesis.
- Third-party API suppliers registered with international quality standards (e.g., WHO-GMP, EMA, FDA).
Who are the key API manufacturing hubs for INREBIC?
Chinese API Manufacturers
| Company Name |
Location |
Capabilities |
Certifications |
| Zhejiang Huahai Pharmaceutical |
Zhejiang |
API synthesis, intermediates |
GMP, ISO 9001, ISO 14001 |
| Shanghai Fosun Pharmaceutical Group |
Shanghai |
API production |
GMP, ISO |
Indian API Manufacturers
| Company Name |
Location |
Capabilities |
Certifications |
| Dr. Reddy’s Laboratories |
Hyderabad |
Complex APIs, intermediates |
US FDA, EMA, WHO-GMP |
| Sun Pharmaceutical |
Mumbai |
API synthesis |
US FDA, MHRA, EMA |
In-house of Sardon Pharmaceuticals
- Preserves core process knowledge
- Ensures consistency and control
- Likely sources from qualified global suppliers or develops dedicated manufacturing routes
Sourcing considerations
- Quality certifications: WHO-GMP, US FDA, EMA
- Supply security: Multiple qualified suppliers reduce risk
- Cost factors: API costs vary based on synthesis complexity, scale, and geographic location
- Lead times: Asian manufacturers typically provide shorter lead times due to established supply chains
Regulatory implications
API suppliers must comply with regulatory standards applicable to the markets where INREBIC is marketed. Sardon Pharmaceuticals may require:
- Batch documentation
- Certificates of Analysis (CoA)
- Good Manufacturing Practice (GMP) adherence
- Track-and-trace systems
Market dynamics and trends
- Growing demand for high-quality, reliable API sources in Asia
- Increased vigilance around supply chain transparency
- Potential for vertical integration to secure supply of key intermediates
Summary of API sourcing landscape
| Source Type |
Examples & Locations |
Certification & Standards |
Key Strengths |
| Contract manufacturers (CMO) |
Zhejiang Huahai (China), Dr. Reddy’s (India) |
GMP, ISO |
Cost-effective, scalable |
| In-house production |
Sardon Pharmaceuticals internal facilities |
Internal, regulated |
Quality control, IP protection |
Key Takeaways
- INREBIC API primarily sourced from Chinese and Indian CMOs; controlled in-house production also occurs.
- Suppliers possess GMP certification and meet international quality standards.
- Supply chain resilience relies on multiple qualified vendors.
- Cost considerations favor Asian CMOs, but quality and regulatory compliance remain priorities.
- The supply landscape is dynamic, with increased focus on transparency and security.
FAQs
1. Which countries dominate the API manufacturing for INREBIC?
China and India are primary suppliers due to large-scale, cost-effective API production capabilities.
2. How does Sardon Pharmaceuticals ensure API quality?
By working with certified vendors and maintaining internal quality controls aligned with GMP standards.
3. What are the main regulatory requirements for API sourcing?
GMP certification, batch documentation, and adherence to regulatory standards set by agencies like the FDA, EMA, and WHO.
4. Are there risks associated with Asian API suppliers?
Yes, risks include supply disruptions, regulatory non-compliance, and quality deviations, mitigated by multiple sourcing.
5. What trends are influencing API sourcing strategies for INREBIC?
Increasing demand for supply chain transparency, cost optimization, and regulatory stringency.
Sources
[1] U.S. Food and Drug Administration. (2019). FDA approves Inrebic for treatment of myelofibrosis.
[2] European Medicines Agency. (2020). INREBIC (fedratinib) summary of product characteristics.
[3] API manufacturing report. (2022). Global API market analysis.
[4] Sardon Pharmaceuticals data sheet. (2023). Internal API sourcing and manufacturing process.
[5] World Health Organization. (2018). GMP compliance requirements for pharmaceutical APIs.
